NCT05832229 (LCN RESCU) is a Phase 2 clinical trial of Rosuvastatin in Cirrhosis, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Who is sponsoring NCT05832229?

NCT05832229 is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

What drugs are being tested in NCT05832229?

Interventions in NCT05832229: Rosuvastatin.

What condition does NCT05832229 study?

NCT05832229 studies Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C.

Is NCT05832229 still recruiting?

NCT05832229 is currently recruiting now. Last updated 13 January 2026.

Last reviewed 2026-01-13 · How we verify

NCT05832229: LCN RESCU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Recruiting now Phase 2 Last updated 13 January 2026

What this trial tests

Phase 2 trial testing Rosuvastatin in Cirrhosis in 256 participants. Currently enrolling.

Timeline

7 December 2023

Primary endpoint
31 August 2029

31 August 2029

Quick facts

Lead sponsor	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	256
Start date	7 December 2023
Primary completion	31 August 2029
Estimated completion	31 August 2029
Sites	13 locations across United States

Drugs / interventions tested

Rosuvastatin (rosuvastatin) — full drug profile →

Conditions studied

Cirrhosis — all drugs for Cirrhosis →
Cirrhosis, Liver — all drugs for Cirrhosis, Liver →
Cirrhosis Early — all drugs for Cirrhosis Early →
Cirrhosis Due to Hepatitis B — all drugs for Cirrhosis Due to Hepatitis B →

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Who can join

Adults 18 to 75, any sex, with Cirrhosis or Cirrhosis, Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Modelling and targeting mechanical forces in organ fibrosis.
Mascharak S, Guo JL, Griffin M, Berry CE, et al · · 2024 · cited 23× · PMID 39552705 · DOI 10.1038/s44222-023-00144-3
A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action.
Zhang S, Ren X, Zhang B, Lan T, et al · · 2024 · cited 18× · PMID 38675679 · DOI 10.3390/molecules29081859
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic.
Suzuki H, Fujiwara N, Singal AG, Baumert TF, et al · · 2025 · cited 9× · PMID 39808821 · DOI 10.1097/hep.0000000000001227
Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications.
Zhao J, Yue P, Mi N, Li M, et al · · 2024 · cited 5× · PMID 39135601 · DOI 10.1515/mr-2024-0029
Preventative Hepatology and the Reduction of All-Cause Mortality in Liver Disease.
Price JC. · · 2023 · cited 2× · PMID 38404419
HMG-CoA Reductase Inhibitors (Statins) May Preserve Hepatic Function and Reduce Portal-Systemic Shunting in Compensated Advanced Chronic Liver Disease: Results From the SHUNT-V Study.
Rahimi RS, Mena E, Lucas KJ, McRae MP, et al · · 2026 · cited 1× · PMID 41586527 · DOI 10.14309/ctg.0000000000000980
Alcohol-related liver disease.
Herms Q, Gratacós-Ginès J, Pose E. · · 2025 · cited 1× · PMID 41059436 · DOI 10.1093/gastro/goaf088
Going beyond the technology: Considerations in translating electronic case report forms.
Krefman AE, Rasmussen LV, Santillanes C, Tull MB, et al · · 2025 · PMID 41743757 · DOI 10.1017/cts.2025.10078

Verify or expand the search:

Other trials of Rosuvastatin

Trials testing the same drug.

NCT07474649 — A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events · Phase 3 · not yet recruiting
NCT07534592 — A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants · Phase 1 · not yet recruiting
NCT07515339 — A Study to Learn More About How Safe Nurandociguat is and How it Affects the Way the Body Processes Rosuvastatin and Dab · Phase 1 · not yet recruiting
NCT07303816 — Statins to Prevent Cancer Associated Blood Clots · Phase 4 · not yet recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting

Other recruiting trials for Cirrhosis

Currently open trials in the same condition.

NCT07322237 — DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis · Phase 4 · recruiting
NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
NCT07461545 — Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS · NA · recruiting
NCT07461532 — Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD · NA · recruiting
NCT07462091 — Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection · NA · recruiting

Other National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) trials

Trials by the same sponsor.

NCT07313787 — Effects of Meal Macronutrients on Postprandial Lipids · Phase 2 · not yet recruiting
NCT07388537 — Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults · not yet recruiting
NCT05713799 — Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity · Phase 2 · not yet recruiting
NCT05722210 — Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant · not yet recruiting
NCT07191561 — Hepatic Lipid Metabolism-Alcohol Use Disorder · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05832229 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Last refreshed: 13 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05832229.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing